Advertisement
Screener

Cue Biopharma, Inc. (CUE) Quick Ratio

2.8 / 5 stars · 68/120 Roast Me

Cue Biopharma, Inc. Quick Ratio

The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

  • Cue Biopharma, Inc. quick ratio for the quarter ending 2026-06-30 was 1.07, a 26.27% decline year-over-year.
  • Cue Biopharma, Inc. quick ratio for the quarter ending 2026-03-31 was 2.94, a 246.87% increase year-over-year.
  • Cue Biopharma, Inc. quick ratio for the quarter ending 2025-12-31 was 2.42, a 41.66% increase year-over-year.
  • Cue Biopharma, Inc. quick ratio for the quarter ending 2025-09-30 was 0.78, a 63.25% decline year-over-year.
  • Cue Biopharma, Inc. quick ratio for fiscal 2025 was 2.42, a 41.66% increase from fiscal 2024.
  • Cue Biopharma, Inc. quick ratio for fiscal 2024 was 1.71, a 41.84% decline from fiscal 2023.
  • Cue Biopharma, Inc. quick ratio for fiscal 2023 was 2.94, a 34.30% decline from fiscal 2022.
  • Cue Biopharma, Inc. quick ratio for fiscal 2022 was 4.47, a 15.25% decline from fiscal 2021.
Available history
2017-12-31 to 2026-06-30
Data captured

Historical Quick Ratio

DateQuick RatioQuick assetsCurrent liabilities
2026-06-301.07$22.77M$21.22M
2026-03-312.94$21.73M$7.39M
2025-12-312.42$32.68M$13.49M
2025-09-300.78$12.09M$15.52M
2025-06-301.46$28.02M$19.25M
2025-03-310.85$13.14M$15.5M
2024-12-311.71$23.4M$13.69M
2024-09-302.12$35.57M$16.79M
2024-06-301.94$31.88M$16.46M
2024-03-312.35$42.43M$18.09M
2023-12-312.94$50.21M$17.08M
2023-09-303.27$56.35M$17.21M
2023-06-303.31$54.04M$16.31M
2023-03-314.09$56.52M$13.81M
2022-12-314.47$51.67M$11.55M
2022-09-302.99$30.52M$10.22M
2022-06-308.03$66.86M$8.32M
2022-03-316.03$68.85M$11.41M
2021-12-315.28$67.51M$12.79M
2021-09-304.45$68.4M$15.36M
2021-06-304.55$75.82M$16.67M
2021-03-314.49$74.67M$16.63M
2020-12-314.68$76.28M$16.32M
2020-09-305.07$72.19M$14.23M
2020-06-304.1$60.98M$14.86M
2020-03-311.99$24.04M$12.09M
2019-12-313.86$45.04M$11.66M
2019-09-303.08$31.99M$10.39M
2019-06-302.2$24.78M$11.27M
2019-03-312.07$21.91M$10.57M
2018-12-313.35$20.8M$6.22M
2018-09-303.46$15.84M$4.59M
2018-06-3015.44$45.74M$2.96M
2017-12-3111.88$63.53M$5.35M

Annual Quick Ratio

DateQuick RatioQuick assetsCurrent liabilities
2025-12-312.42$32.68M$13.49M
2024-12-311.71$23.4M$13.69M
2023-12-312.94$50.21M$17.08M
2022-12-314.47$51.67M$11.55M
2021-12-315.28$67.51M$12.79M
2020-12-314.68$76.28M$16.32M
2019-12-313.86$45.04M$11.66M
2018-12-313.35$20.8M$6.22M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
MACROGENICS INC (MGNX)United States$0.242B-20.11
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55